Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1987 1
1989 1
1991 7
1992 9
1993 10
1994 20
1995 18
1996 10
1997 12
1998 14
1999 4
2000 6
2001 4
2002 1
2003 5
2004 3
2005 11
2006 9
2007 5
2008 5
2009 7
2010 9
2011 9
2012 4
2013 10
2014 7
2015 9
2016 16
2017 10
2018 4
2019 7
2020 10
2021 13
2022 20
2023 13
2024 15
2025 12
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Nononcologic Embolization.
De la Garza-Ramos C, Salei A, Caridi TM. De la Garza-Ramos C, et al. Semin Intervent Radiol. 2022 Nov 17;39(4):416-420. doi: 10.1055/s-0042-1758077. eCollection 2022 Aug. Semin Intervent Radiol. 2022. PMID: 36406022 Free PMC article. Review.
Apart from oncologic indications, embolization is used to treat a wide range of benign pathology, including uterine fibroids and benign prostatic hyperplasia. While various particulate embolic agents are successfully used for benign embolization …
Apart from oncologic indications, embolization is used to treat a wide range of benign pathology, including uterine fibroids and b …
Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Pliskin M, Beahrs JR, Prall D, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Tadros NN, Gange SN, Roehrborn CG. McVary KT, et al. J Urol. 2021 Sep;206(3):715-724. doi: 10.1097/JU.0000000000001778. Epub 2021 Apr 19. J Urol. 2021. PMID: 33872051 Clinical Trial.
PURPOSE: We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezum ) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia. MATERIALS AND METHODS: A tota …
PURPOSE: We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezum ) for treatmen …
Natural history of benign prostatic hyperplasia.
Jacobsen SJ, Girman CJ, Lieber MM. Jacobsen SJ, et al. Urology. 2001 Dec;58(6 Suppl 1):5-16; discussion 16. doi: 10.1016/s0090-4295(01)01298-5. Urology. 2001. PMID: 11750242 Review.
Studies in varied settings have provided estimates of the prevalence of surrogate markers of benign prostatic hyperplasia (BPH). In population-based studies, the prevalence of moderate-to-severe lower urinary tract symptoms and depressed peak urinary flow rat …
Studies in varied settings have provided estimates of the prevalence of surrogate markers of benign prostatic hyperplasia …
Benign prostatic hyperplasia: treat or wait?
Davidson JH, Chutka DS. Davidson JH, et al. J Fam Pract. 2008 Jul;57(7):454-63. J Fam Pract. 2008. PMID: 18625168 Review.
Rule out potential causes of lower urinary tract symptoms with a thorough medical history, focused physical exam (including digital rectal examination and neurological assessments), and appropriate laboratory evaluations. When choosing treatment for benign prostatic …
Rule out potential causes of lower urinary tract symptoms with a thorough medical history, focused physical exam (including digital rectal e …
Risk factors for benign prostatic hyperplasia.
Jacobsen SJ. Jacobsen SJ. Curr Urol Rep. 2007 Jul;8(4):281-8. doi: 10.1007/s11934-007-0074-9. Curr Urol Rep. 2007. PMID: 18519012 Review.
This review summarizes recent findings regarding risk factors for benign prostatic hyperplasia (BPH), including new data on hormonal factors, growth factors, comorbid conditions and lifestyle, diet, and exercise as they relate to BPH. ...
This review summarizes recent findings regarding risk factors for benign prostatic hyperplasia (BPH), including new dat …
MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update.
Diaz TA, Benson B, Clinkenbeard A, Long JR, Kawashima A, Yano M. Diaz TA, et al. AJR Am J Roentgenol. 2022 Jan;218(1):88-99. doi: 10.2214/AJR.21.26278. Epub 2021 Jul 14. AJR Am J Roentgenol. 2022. PMID: 34259037 Review.
Transurethral resection of the prostate is the most commonly performed procedure for the management of patients with lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH). However, in recent years, various minimally invasive surgical t …
Transurethral resection of the prostate is the most commonly performed procedure for the management of patients with lower urinary tract sym …
Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review.
Kingsley R, Tyree S, Jarsania D, Edquist C, Palmer A, Gerberi D, Wilfahrt R, Pagali S. Kingsley R, et al. Int Neurourol J. 2024 Sep;28(3):171-180. doi: 10.5213/inj.2448266.133. Epub 2024 Sep 30. Int Neurourol J. 2024. PMID: 39363407 Free PMC article.
Alpha-1 adrenergic receptor (alpha1-AR) antagonists are commonly used for management of benign prostatic hyperplasia or hypertension. Some studies have shown a potential link between alpha1-AR antagonist use and cognitive impairment. ...
Alpha-1 adrenergic receptor (alpha1-AR) antagonists are commonly used for management of benign prostatic hyperplasia or …
Minimally invasive therapies for benign prostatic hyperplasia.
Blute ML, Larson T. Blute ML, et al. Urology. 2001 Dec;58(6 Suppl 1):33-40; discussion 40-1. doi: 10.1016/s0090-4295(01)01301-2. Urology. 2001. PMID: 11750248 Review.
Currently, 3 categories of treatment are available for men with benign prostatic hyperplasia (BPH): (1) medicine, such as alpha-blockers and finasteride; (2) minimally invasive treatment, such as transurethral microwave thermotherapy and interstitial ablation …
Currently, 3 categories of treatment are available for men with benign prostatic hyperplasia (BPH): (1) medicine, such …
Benign Prostatic Hyperplasia Implications for Pharmacologic Treatment and Perioperative Care.
Leedahl DD, Vo PH, Maxson PM, Lovely JK. Leedahl DD, et al. J Pharm Pract. 2013 Feb;26(1):52-8. doi: 10.1177/0897190012451913. Epub 2012 Jul 13. J Pharm Pract. 2013. PMID: 22797835 Review.
This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign pr …
This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations fo …
The association of benign prostatic hyperplasia and cancer of the prostate.
Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. Bostwick DG, et al. Cancer. 1992 Jul 1;70(1 Suppl):291-301. doi: 10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4. Cancer. 1992. PMID: 1376199 Review.
There are a number of similarities between benign prostatic hyperplasia (BPH) and cancer. Both display a parallel increase in prevalence with patient age according to autopsy studies (86.2% and 43.6%, respectively, by the ninth decade), although cancer lags b …
There are a number of similarities between benign prostatic hyperplasia (BPH) and cancer. Both display a parallel incre …
294 results